Painceptor Pharma announces collaboration with Argenta Discovery
PainCeptor Pharma Corp. announced that it has entered into a development collaboration with Argenta Discovery Ltd., a contract and respiratory drug development company. Under the terms of the agreement, scientists from the two companies will exploit Argenta's expertise in computer-aided drug design (CADD) and medicinal chemistry to accelerate PainCeptor's ASIC (acid-sensing ion channel) development program for pain therapeutics, targeting these sensory mechanisms which are associated with a variety of pain-related conditions, including cancer and arthritis.
Financial terms of the deal were not disclosed, but the agreement does provide options to expand the relationship.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.